Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly EPS; no daily interpolation.
Limited quarterly history available
EPS needs at least three reported quarters before a meaningful chart is shown.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
-0.92
EARNINGS PER SHARE (EPS) AVG 3Y
-0.62
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Market Cap
$5.89M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.92
3Y Avg
-0.62
5Y Avg
N/A
Market Cap
$5.92M
Earnings Per Share (EPS)
-1.35
TTM Avg
-3.54
3Y Avg
-9.29
5Y Avg
-9.12
Market Cap
$5.98M
Earnings Per Share (EPS)
-2.92
TTM Avg
-6.51
3Y Avg
-19.53
5Y Avg
-13.36
Market Cap
$6.08M
Earnings Per Share (EPS)
537.52
TTM Avg
197.33
3Y Avg
123.75
5Y Avg
69.48
Market Cap
$5.63M
Earnings Per Share (EPS)
-3.55
TTM Avg
-11.46
3Y Avg
-17.07
5Y Avg
-17.09
Market Cap
$5.57M
Earnings Per Share (EPS)
-9.46
TTM Avg
-14.22
3Y Avg
-49.51
5Y Avg
-78.92
Market Cap
$6.21M
Earnings Per Share (EPS)
-1.26
TTM Avg
-1.73
3Y Avg
-1.08
5Y Avg
-0.87
Market Cap
$6.13M
Earnings Per Share (EPS)
-4.57
TTM Avg
-13.10
3Y Avg
-16.05
5Y Avg
-14.80
Market Cap
$5.36M
Earnings Per Share (EPS)
-2.30
TTM Avg
-6.97
3Y Avg
-88.06
5Y Avg
-105.56
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) | $5.89M | N/A | -0.92 | -0.62 | N/A |
| Lucyd, Inc (LUCY)vs › | $5.92M | -1.35 | -3.54 | -9.29 | -9.12 |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | -2.92 | -6.51 | -19.53 | -13.36 |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.08M | 537.52 | 197.33 | 123.75 | 69.48 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | -3.55 | -11.46 | -17.07 | -17.09 |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.57M | -9.46 | -14.22 | -49.51 | -78.92 |
| Biomerica, Inc. (BMRA)vs › | $6.21M | -1.26 | -1.73 | -1.08 | -0.87 |
| Femasys Inc. (FEMY)vs › | $6.13M | -4.57 | -13.10 | -16.05 | -14.80 |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | -2.30 | -6.97 | -88.06 | -105.56 |
| Lunai Bioworks Inc. (LNAI)vs › | $5.36M | -61.25 | -79.52 | -97.16 | -86.80 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.43 |
| 2024-12-31 | -0.42 |
| 2023-12-31 | -0.31 |
| 2022-12-31 | -0.32 |
| 2021-12-31 | -0.15 |
